Trilipix approved for cholesterol management

Abbott’s Trilipix (fenofibric acid) delayed-release capsules have been approved for use along with diet to help lower triglycerides and LDL cholesterol and to raise HDL cholesterol in patients with lipid problems. In three randomized, double-blind, controlled studies of 2698 patients with mixed dyslipidemia, Trilipix in combination with rosuvastatin, atorvastatin and simvastatin significantly improved HDL and triglycerides compared to statin therapy alone, and significantly improved LDL compared to Trilipix alone. All of the combinations and the statins had clinically meaningful reductions in LDL.

Trilipix is expected to be available by the end of December 2008 in 45mg and 135mg dosage strengths.

For more information call (800) 633-9110 or visit www.trilipix.com.